ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL

被引：0
|
作者：
McEwan, P. [1 ]
Evans, L. M. [2 ]
Bergenheim, K. [3 ]
机构：
[1] CRC, Cardiff, S Glam, Wales
[2] Univ Wales Hosp, Cardiff, Vale Glamorga, Wales
[3] AstraZeneca, Molndal, Sweden
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72108-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A293 / A293
页数：1
相关论文
共 50 条
  • [21] The platelets characteristics in type 2 diabetes mellitus (T2DM)
    Buryachkovskaya, L.
    Uchitel, I. A.
    Sumarokov, A. B.
    Docenko, U., V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 931 - 931
  • [22] Microvascular complications in type 2 diabetes mellitus (T2DM).
    Cheung, AT
    Ramanujam, S
    Duong, PL
    Schauer, D
    Chan, LS
    Dwyre, DM
    Larkin, EC
    FASEB JOURNAL, 2002, 16 (04): : A208 - A208
  • [23] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS A DPP-4 INHIBITOR IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Roudaut, M.
    VALUE IN HEALTH, 2013, 16 (07) : A440 - A440
  • [24] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA
    Teschemaker, A. R.
    Neslusan, C.
    Sabapathy, S.
    Yoong, K.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A63
  • [25] Safety and Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus (T2DM) in South Korea
    Kim, Hun-Sung
    Min, Kyungwan
    Kim, Sang Soo
    Kim, Eun Sook
    Chung, Yoon-Sok
    Chung, Choon H.
    Yun, Jae-Seung
    Kim, Won
    Kim, Dong Han
    Yoo, Soon Jib
    DIABETES, 2024, 73
  • [26] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [27] RESEARCH ON THE INCIDENCE AND COST OF HYPOGLYCEMIA EPISODE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Zheng, Y.
    Wu, J.
    Oesterle, A.
    VALUE IN HEALTH, 2012, 15 (07) : A504 - A505
  • [28] Assessing MicroRNA-375 Levels in Type 2 Diabetes Mellitus (T2DM) Patients and Their First-Degree Relatives with T2DM
    Wu, Xu
    Li, Yashan
    Man, Baohua
    Li, Dexuan
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 1445 - 1451
  • [29] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
    Thompson, G.
    Schroeder, M.
    Neslusan, C.
    Willis, M.
    Johansen, P.
    Teschemaker, A.
    DIABETOLOGIA, 2014, 57 : S330 - S330
  • [30] COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE®) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN TURKEY BASED EMPA-REG OUTCOME DATA
    Oksuz, E.
    Malhan, S.
    Kamaci, E.
    Urganci, B.
    Tetik, E.
    Temizhan, A.
    Ersoy, R.
    Balbay, Y.
    VALUE IN HEALTH, 2017, 20 (09) : A479 - A479
12345